• Tag results for Dr reddy

Rupee rises by 14 paise against dollar; Sensex up 101 points

Most Asian markets were trading higher as solid economic data from the United States and Germany reinforced investors' optimism.

published on : 4th January 2018

Dr Reddy's Labs shares extend losses, down 3 per cent

Meanwhile, BSE earlier in the day sought clarification from the company on reports that Dr Reddy's shares fell on the buzz of issues raised in EIR for Duvvada plant.

published on : 3rd January 2018

Dr Reddy's gets EIR for Vizag plant, but inspection not closed

Dr Reddy's Laboratories today said it has received an establishment inspection report from the US health regulator for its formulation manufacturing facility at Duvvada in Visakhapatnam.

published on : 21st November 2017

Prescient messages about Indian companies circulate in WhatsApp groups

Three days before Dr. Reddy's Laboratories Ltd announced quarterly results this summer, a message circulated to a private WhatsApp group saying the Indian drugmaker would not post good numbers.

published on : 16th November 2017

Dr Reddy's Laboratories Q2 consolidated net profit down 1 per cent to Rs 305 crore

The drug major had posted a net profit of Rs 308.9 crore in July-September a year ago, DRL said in a filing to BSE.

published on : 31st October 2017

Dr Reddy's stock ends 3 per cent up; market capitalization rises by Rs 1,019 crore

The company said it has received an establishment inspection report from FDA for a unit at its Srikakulam formulations facility.

published on : 28th September 2017

Dr Reddy's shares slip nearly three percent, mcap drops by Rs 1,082 crore

In terms of equity volume, 1.57 lakh shares of the company were traded on BSE and over 17 lakh shares changed hands on NSE during the day.

published on : 8th September 2017

Dr Reddy's gets favourable verdict in patent litigation in US

US District court has issued a judgement in favour to the drug firm, ruling that proposed generic version of Suboxone sublingual film does not infringe the patent of Indivior.

published on : 1st September 2017

Dr Reddy's faces class action suit in US court

DRL has said a law firm representing a purported investor has filed a class action suit in a USA court against the company and its key executives for alleged violations of American federal securities.

published on : 28th August 2017

Dr Reddy's out-licenses manufacturing, marketing rights of psoriasis drug to Encore Dermatology

Dr Reddy's Laboratories today said it has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology Inc.     

published on : 22nd August 2017

Dr Reddy's sees no impact from NPPA notice

A recent government notice that said the company is selling a high blood pressure drug that lacks the pricing regulator's approval.

published on : 19th May 2017

US bans Indian drugmaker Divi's factory, shares hit three-year low

The FDA also found violations of manufacturing standards at Dr Reddy's Laboratories Ltd's drug plant, also in Vizag, during an inspection.

published on : 22nd March 2017

634 drugs suspected to be not compliant with government price ceiling

Companies are allowed to hike prices of essential drugs by up to 10 per cent in a year.

published on : 23rd February 2017

Dr Reddy's shares down 4 per cent after adverse court ruling in US

The patent infringement case was over an anti-nausea injection Aloxi meant for dealing with the side-effects of chemotherapy.

published on : 16th February 2017

Dr Reddy's, Aurobindo recall drugs from US market

A notification by the FDA said recalls are voluntarily initiated by the two companies.

published on : 15th February 2017